Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2474-2481

  Keyes, Kristan A ^a   Albella, Beatrix ^b   LoRusso, Patricia M ^a   Bueren, Juan A ^b   Parchment, Ralph E ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Ctr Investigations Ener E   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; GEMCITABINE; MELPHALAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL POPULATION; COLONY FORMING UNIT GM; COLONY FORMING UNIT S; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HEMATOPOIESIS; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELL COUNT; BLOOD PLATELETS; BONE MARROW; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MELPHALAN; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEUTROPENIA; NEUTROPHILS; PHENYLENEDIAMINES; RANDOM ALLOCATION; STEM CELLS; TIME FACTORS;

EID: 0034083408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Green, J. A., Dawson, A. A., Fell, L. F., and Murray, S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br. J. Clin. Pharmacol., 9: 511-514, 1980.
2. Hryniuk, W., and Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2: 1281-1287, 1984.
3. Levin, L., and Hryniuk, W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol., 5: 756-767, 1987.
4. Hryniuk, W. M. The importance of dose intensity in the outcome of chemotherapy. In: V. T. DeVita, S. Hekkman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 121-139. Philadelphia: Lippincott Co., 1988.
5. Klasa R. J., Murray, N., and Coldman, A. J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol., 9: 449-508, 1991.
6. Font, A., Moyano, A. J., Puerto, J. M., Tres, A., Garcia-Giron, C., Barneto, I., Anton, A., Sanchez, J. J., Salvador, A., and Rosell, R. Increasing dose intensity of cisplatin-etoposide in advanced non small-cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer (Phila.)., 15: 855-863, 1999.
7. Henderson, I. C., Hayes, D. F., and Gelman, R. Dose-response in the treatment of breast cancer: a critical review. J. Clin. Oncol., 9: 1501-1515, 1988.
8. Frei, E., Elias, A., Wheeler, C., Richardson, P., and Hryniuk, W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin. Cancer Res., 4: 2027-2037, 1998.
9. Lokich, J., and Anderson, N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 antineoplastic agents. Ann. Oncol., 8: 15-25, 1997.
10. El-Beltagi, H. M., Martens, A. C., Lelieveld, P., Haroun, E. A., and Hagenbeek, A. Acetyldinaline: a new oral cytotoxic drug with impressive differential activity against leukemic and normal stem cells -preclinical studies in a relevant rat model for human myelocytic leukemia. Cancer Res., 53: 3008-3014, 1993.
11. LoRusso, P. M., Demchick, L., Foster, B., Knight, J., Bissery, M., Polin, L. M., Leopold, W. R., and Corbett, T. H. Preclinical antitumor activity of CI-994. Investig. New Drugs., 14: 349-356, 1996.
12. Graziano, M. J., Pilcher, G. D., Walsh, K. M., Kasali, O. B., and Radulovic, L. Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs. Investig. New Drugs. 15: 295-310, 1997.
13. Foster, B. J., Jones, L., Wiegand, R., LoRusso, P. M., and Corbett, T. H. Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994. Investig. New Drugs, 15: 187-194, 1997.
14. Veerman, G., Ruiz Van Haperen, V. W., Noordhuis, P., Braakhuis, B. J., Pinedo, H. M., and Peters, G. J. Antitumor activity of prolonged as compared with bolus administration of 2′2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother. Pharmacol., 38: 335-342, 1996.
15. Braakhuis, B. J., Ruiz van Haperen, V. W., Boven, E., Veerman, G., and Peters, G. J. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin. Oncol., 22: 42-46, 1995.
16. Ruiz van Haperen, V. W., Veerman, G., Boven, E., Noordhuis, P., Vermorken, J. B., and Peters, G. J. Schedule dependence of sensitivity to 2′2′-difluorodeoxycytidine in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem. Pharmacol., 48: 1327-1339, 1994.
17. Varas, F., Bernard, A., Almendral, J. M., and Bueren, J. A. Relevance of myeloablative conditioning in the engraftment of limiting numbers of normal and genetically marked lympho-hematopoietic stem cells. Bone Marrow Transplant., 18: 981-984, 1996.
18. Harrison, D. E., Jordan, C., Zhong, R-K., and Astle, C. Primitive hematopoietic stem cell: direct assay of the most productive populations by competitive repopulation with simple binomial, correlation, and covariance calculations. Exp. Hematol., 21: 553-559, 1993.
19. Parchment, R. E., Gordon, M., Grieshaber, C. K., Sessa, C., Volpe, D., and Ghielmini, M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann. Oncol., 9: 357-364, 1998.
20. LoRusso, P. M., Wozniak, A., Foster, B., Parchment, R., Volpe, D., Meyer, M., Radulovic, L., Corbett, T., and Valdivieso, M. Phase I Trial of Daily Dosing of Acetyldinaline (CI-994). 9th NCI-EORTC Symposium on New Drugs. I. Cancer Therapy, Amsterdam, March 12-15, 1996.
21. Dorr, R. T., and Von Hoff, D. D. (eds.) Cancer Chemotherapy Handbook. Norwalk, CT: Appleton & Lange, 1994.
22. Taylor, C. W., Alberts, D. S., Ketcham, M. A., Satterlee, W. G., Holdworth, M. T., Plezia, P. M., Peng, V. M., McCloskey, T. M., Roe, D. J., and Hamilton, M. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J. Clin. Oncol., 7: 1733-1740, 1989.